DrugPatentWatch Database Preview
RYANODEX Drug Profile
Which patents cover Ryanodex, and what generic alternatives are available?
This drug has eight patent family members in five countries.
The generic ingredient in RYANODEX is dantrolene sodium. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.
Summary for RYANODEX
| International Patents: | 8 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 47 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,131 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | RYANODEX at DailyMed |
Pharmacology for RYANODEX
| Drug Class | Skeletal Muscle Relaxant |
| Physiological Effect | Decreased Striated Muscle Contraction Decreased Striated Muscle Tone |
Medical Subject Heading (MeSH) Categories for RYANODEX
Synonyms for RYANODEX
| 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione |
| 1-(((E)-[5-(4-Nitrophenyl)-2-furyl]methylidene)amino)-2,4-imidazolidinedione # |
| 1-((5-(4-Nitrophenyl)furfurylidene)amino)imidazolidine-2,4-dione, sodium salt |
| 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin |
| 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium |
| 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium salt hydrate |
| 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione |
| 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione |
| 1-[(5--(p-Nitro-phenyl)-fur-furyl-idene)-amino]-hydan-toin sodium salt |
| 1-[(5-[p-Nitrophenyl]-furfurylidene)amino]hydantoin |
| 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione |
| 1-[[[5-(4-Io>>u+/-(1/2))-2-ss>>a<<>>u]NC(1/4)x>>u degrees +/->>u]-2,4-ssassosso paragraph signthornI feminine AAENI |
| 1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione Sodium Salt Hemiheptahydrate |
| 1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolinedione sodium salt |
| 1-[[5-(p-Nitrophenyl)furfurylidene]amino]hydantoin |
| 1-[5-(4-nitro-phenyl)-furan-2-ylmethyleneamino]-imidazolidine-2,4-dione |
| 1-[5-(4-Nitrophenyl)furfurylideneamino]hydantoin Sodium Salt |
| 14663-23-1 |
| 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)- |
| 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt |
| 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt, hydrate (2:7) |
| 2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]- |
| 2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-, sodium salt, hydrate |
| 24868-20-0 |
| 28F0G1E0VF |
| 2C14H9N4O5.2Na |
| 2C14H9N4O5.2Na.7H2O |
| 7261-97-4 |
| AB0011237 |
| AC1O7G8U |
| AC1OC9NE |
| AKOS015895197 |
| AKOS015895198 |
| Ambap14663-23-1 |
| anhydrous dantrolene sodium |
| B6329 |
| BCBcMAP01_000067 |
| BIDD:GT0187 |
| BPBio1_000246 |
| BRD-K81272440-001-02-6 |
| BRD-K81272440-236-05-1 |
| BRN 0705189 |
| BSPBio_000222 |
| BSPBio_001305 |
| BSPBio_003074 |
| C06939 |
| C07933 |
| C14H10N4O5 |
| C14H9N4O5.Na |
| CCG-220291 |
| CCG-40324 |
| CHEBI:4317 |
| CHEBI:4318 |
| CHEMBL1201288 |
| CHEMBL928 |
| CPD000326766 |
| CS-5234 |
| D02347 |
| D0I8DD |
| D3996 |
| Dantamacrin |
| Dantrium |
| Dantrium (TN) |
| Dantrium Intravenous |
| Dantrix |
| Dantrolen (TN) |
| dantrolene |
| Dantrolene (sodium salt) |
| Dantrolene (sodium) |
| Dantrolene (USAN/INN) |
| Dantrolene [USAN:BAN:INN] |
| Dantrolene [USAN:INN:BAN] |
| DANTROLENE SODIUM |
| Dantrolene Sodium (anhydrous) |
| Dantrolene sodium [USAN:BAN:JAN] |
| Dantrolene sodium anhydrous |
| Dantrolene sodium hemiheptahydrate |
| Dantrolene sodium salt |
| Dantrolene, Sodium Salt |
| Dantroleno |
| Dantroleno [INN-Spanish] |
| Dantrolenum |
| Dantrolenum [INN-Latin] |
| DB01219 |
| EINECS 230-684-8 |
| EINECS 238-706-8 |
| EU-0100424 |
| F 440 |
| F-368 |
| F-440 |
| F64QU97QCR |
| HMS1361B07 |
| HMS1568L04 |
| HMS1791B07 |
| HMS1989B07 |
| HMS2092N12 |
| HMS2095L04 |
| HMS3261E10 |
| HMS3266G14 |
| HMS3402B07 |
| HMS502M20 |
| HSDB 3050 |
| HY-14657 |
| Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)- |
| Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt |
| Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt, hydrate (2:7) |
| I06-0335 |
| I06-0336 |
| IDI1_000898 |
| IDI1_033775 |
| Lopac0_000424 |
| LS-174074 |
| LS-76264 |
| LS-76265 |
| MFCD00079130 |
| MLS000859905 |
| MLS002153441 |
| MolPort-003-666-797 |
| MolPort-006-069-178 |
| NCGC00093847-01 |
| NCGC00163132-01 |
| NCGC00163402-01 |
| NCGC00163402-02 |
| NCGC00163402-03 |
| NCGC00188950-01 |
| OZOMQRBLCMDCEG-VIZOYTHASA-N |
| potassium 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-4-oxo-5H-imidazol-2-olate |
| Prestwick2_000291 |
| Prestwick3_000291 |
| R452 |
| SAM002703135 |
| SCHEMBL12417164 |
| SCHEMBL40893 |
| SMR000326766 |
| sodium 1-[(E)-{[5-(4-nitrophenyl)furan-2-yl]methylidene}amino]-4-oxo-5H-imidazol-2-olate |
| sodium 3-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-2,5-dioxoimidazolidin-1-ide |
| sodium 3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4H-imidazol-2-olate |
| Sodium dantrolene |
| Sodium, Dantrolene |
| Spectrum5_001752 |
| ST51052737 |
| UNII-28F0G1E0VF |
| UNII-F64QU97QCR |
| ZINC7997966 |
US Patents and Regulatory Information for RYANODEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for RYANODEX
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,789,090 | Treatment using dantrolene | ➤ Sign Up |
| 9,271,964 | Treatment using dantrolene | ➤ Sign Up |
| 9,603,840 | Treatment using dantrolene | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for RYANODEX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005013919 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 03000057 | ➤ Sign Up |
| European Patent Office | 1603513 | ➤ Sign Up |
| Canada | 2516667 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
